PCSA — Processa Pharmaceuticals Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Processa Pharma, Solaredge, Immix Biopharma
Processa Pharma up as gastric disorder drug improves symptoms in study
Brief: Processa Pharmaceuticals Announces PCS12852 Successfully Improves The Clinical Symptoms Associated With Gastroparesis In Phase 2A Trial
Processa Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Processa Pharmaceuticals Announces Third Quarter Financial Results, Provides Corporate Update
Processa Pharmaceuticals Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Processa Pharmaceuticals To Discuss Q3 Results On Nov 8
U.S. STOCKS ON THE MOVE-Processa Pharma, CenterPoint Energy
Processa Pharma rises on positive results from early-stage cancer therapy trial
Brief: Processa Pharmaceuticals Successfully Identifies Next Generation Capecitabine Dosage Regimens For Phase 2B Trial
Brief: Processa Pharmaceuticals Provides Update On Enrollment Across All Clinical Programs
Processa Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Processa Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Processa Pharmaceuticals Announces Q1 2022 Results
Processa Pharmaceuticals Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Processa Doses Patient In Amended Phase 1B Protocol For PCS6422 Combined With Capecitabine
Processa Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Processa Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Processa Pharmaceuticals Files Prospectus Relating To Sale Of Up To $15.0 Million Of Shares Co May Sell To Lincoln Park Capital